What's Happening?
Kos Biotechnology Partners, a global life sciences investment firm based in New York and Athens, Greece, has announced the third closing of its inaugural global life sciences fund, bringing total capital commitments to $123 million. The fund, which initially
launched in December 2025, has received backing from a syndicate of prominent institutional investors, including the Hellenic Development Bank of Investments, and global family offices. Kos Biotechnology Partners is the first life sciences-dedicated investment fund in Greece and represents the largest launch of a venture capital fund in Greece's history. The firm aims to invest strategically across all stages of development, from company formation through Series C, targeting high-impact investments in biotech, pharma services, and tech-enabled technologies.
Why It's Important?
The establishment of Kos Biotechnology Partners' fund is significant as it bridges the US biopharma ecosystem with Europe, particularly Greece, which is seeing its largest venture capital fund launch in history. This fund is poised to enhance the life sciences sector by supporting innovative therapeutic breakthroughs and tech-driven platforms. The convergence of novel biology with data science and advanced computing is creating unprecedented opportunities to address complex diseases, and Kos aims to leverage this by backing entrepreneurs who are redefining the standard of care. The fund's strategic investments could accelerate drug discovery and development, potentially leading to significant advancements in healthcare and economic growth in both the US and Europe.
What's Next?
Kos Biotechnology Partners plans to continue its investment strategy by completing additional investments later this year. The firm has already led a financing round for tech-enabled pharma services provider Epikast and made a strategic investment in a San Francisco-based biotechnology company. The fund will leverage its advisory network, comprising industry leaders from the Greek diaspora in the United States, to help portfolio companies scale globally. This approach is expected to foster cross-border collaboration and innovation, further strengthening the life sciences ecosystem.
